Virtus Health (ASX:VRT) share price shrugs off latest acquisition hurdle

The Virtus share price was unfazed by today's seemingly unfortunate news.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Virtus Health Ltd (ASX: VRT) share price spent most of today in the green despite its planned acquisition being faced with a new challenge.

The company is waiting to complete its acquisition of Adora Fertility and 3 day hospitals, together known as the Adora Businesses. Currently, Healius Ltd (ASX: HLS) owns the Adora Businesses.

However, today Virtus announced the Australian Competition and Consumer Commission (ACCC) is planning to stop the acquisition from being finalised.

Despite the apparent bad news, Virtus performed quite well on the ASX today.

As of Wednesday's close, the Virtus share price is $5.47, 0.37% higher than Tuesday's closing price.

For context, the S&P/ASX 200 Index (ASX: XJO) fell 0.07% today.

Let's take a closer look at the new hurdle facing the healthcare company specialising in fertility treatments and day hospital services.

a man in a suit holds up a hand and a stop sign at a roadblock positioned over a bitumen road .

Image source: Getty Images

Virtus unfazed by ACCC roadblock

The Virtus share price gained today despite announcing seemingly unfortunate news.

The company has had its plans to acquire Adora Fertility and 3 day hospitals halted by the ACCC.

According to Virtus, the watchdog intends to seek an interim order from the Federal Court to prevent the acquisition's completion despite the ACCC's public review not being finalised.

However, Virtus is still planning to complete the acquisition. It said it will defend any proceedings.

The company also noted it has kept the ACCC in the loop throughout the acquisition process.

Virtus stated it has "constructively engaged" with the watchdog since it announced it would conduct a public review process of the acquisition

Virtus first announced its plans to acquire Adora Fertility and the 3 day hospitals back in August. It agreed to pay $45 million for the businesses. The funds were to come from a now-completed $35 million capital raise and existing cash reserves.

Virtus share price snapshot

Right now, the Virtus share price is around 3% higher than it was at the start of 2021. It is also 23% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Virtus Health Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »

Health professional looking at a laptop.
Earnings Results

Cogstate posts record FY26 earnings, boosts dividend

Cogstate delivers record FY26 earnings growth and increases its dividend as it invests in AI-driven expansion.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

CSL earnings: FY26 sees reset and path to future growth

The biotech giant has released its eagerly anticipated results this morning.

Read more »

A man looking at his laptop and thinking.
Earnings Results

Cochlear posts FY26 profit at top end of guidance with new product momentum

Management is guiding to a profit rebound in FY 2027.

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Mesoblast shares are up sharply. Is this biotech still undervalued?

Mesoblast faces big risks, but brokers see substantial upside if successful.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »